InspireMD Aktie Logo
US45779A8466
A3CMP3
NSPR

InspireMD Aktie

Loading quotes...

Forecast

The analysts' average price target is €4.09 (+686.54%). The median is €4.09 (+686.54%).

Buy
  6
Hold
  1
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, InspireMD Aktie had revenue of €1.98m and net profit of -€8.62m
(EUR) September 2026
YoY
Revenue 1.98m 7.93%
Gross profit 211.88k 71.22%
Net profit -8.62m 20.41%
EBITDA -8.62m 19.60%

Fundamentals

Metric Value
Market capitalization
€27.21m
Number of shares
46.49m
52-week high/low
€2.02 - €0.39
Dividends No
Beta
0.91
P/E ratio
-1.44
PEG ratio
-0.02
P/B ratio
2.54
P/S ratio
2.84

Company profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Name
InspireMD Aktie
CEO
Marvin L. Slosman
Headquarters Miami, fl
Israel
Website
Industry
Household Durables
IPO
12/04/2011
Employees 127

Ticker symbols

Exchange Symbol
NASDAQ
NSPR
Frankfurt
II2.F
MĂĽnchen
II2.MU
DĂĽsseldorf
II2.DU
🍪

Parqet  uses cookies. Learn more